A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
ConditionAdvanced Cancers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.
About this trial
TQB3107 is an target inhibitor that binds to target to induce apoptosis and inhibits the proliferation of a variety of tumor cells. This is a clinical study to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).
Eligibility criteria
Qualifiers
18 years ≤ age≤ 75 years (calculated from the date of signing the informed consent); Score 0~1 point, estimated survival ≥ 3 months；
Advanced malignant tumor；
The major organs are functioning well；
Negative serum pregnancy test within 7 days prior to the first dose and must be a non-lactating subject, female and male subjects of childbearing potential should agree to use contraception throughout the study and for 6 months after the study ends;
Disqualifiers
Hematologic malignancy has or is suspected to involve the central nervous system, or primary central nervous system lymphoma;
Received any anti-cancer therapy such as major surgery, chemotherapy and/or radiotherapy, immunotherapy, or targeted therapy within 4 weeks prior to the first dose;
Combined with severe or not well-controlled diseases, which the investigator judges to be at greater risk of entering this study；
Those with a history of drug addiction or substance abuse；
Trial design
Treatments tested in this trial
- TQB3107 Tablets
Treatment groups
140 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov